AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04244734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Treatment Protocol-MotoMED®
Description: Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)
Study NCT03434834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography
Description: OCT measurements of 5 locations in the esophagus
Study NCT04200677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
Study NCT01535482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
Study NCT04200677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Monophasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
Study NCT04200677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
Study NCT04200677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
Study NCT01535482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
Study NCT00272181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxinium
Description: Intratumoral administration of Proxinium directly to target tumors.
Study NCT02052973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis varnish
Description: Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
Study NCT04200677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
Study NCT03589742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AblaView® Ablation Catheter
Description: The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
Study NCT01259011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the SPIRIT intervention
Description: the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
Study NCT02464982 — intervention group
Intervention type: PROCEDURE
Intervention: Tattoo
Description: tattoo device with EC standards, and sterile single-use only needle
Study NCT01958086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Communication System
Description: NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
Study NCT04103450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: oral administration
Study NCT04200677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 25 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
Study NCT01360944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical, 100 microgram
Study NCT01360944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: reference
Description: once daily, 100 microgram
Study NCT02386956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active stretching
Description: 10 minutes of active stretching of the posterior muscle chain with RPG techniques
Study NCT02386956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching
Description: 10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
Study NCT01360944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reference
Description: once daily, 100 microgram
Study NCT02902744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILUVIEN®
Description: Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
Study NCT02221180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
Study NCT02386956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 10 minutes with the patient lying on a machine off of magnetotherapy
Study NCT01139151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 Day Thiarabine
Description: Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3
Study NCT01139151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Day Thiarabine
Description: Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
Study NCT04342247 — intervention group
Intervention type: DRUG
Intervention: external testosteron
Description: external testosteron
Study NCT02221180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
Study NCT02221180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
Study NCT01180127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol containing food product
Description: 12 weeks, 2X/day, 20g serving
Study NCT01180127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: 4X/week, 1 hour/session at 75% maximum HR
Study NCT01180127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food product lacking flavanol
Description: 20 g serving, 2X/day, food additive lacking flavonol
Study NCT01180127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food product lacking flavanol
Description: 20 g serving, 2X/day, food additive lacking flavonol
Study NCT01180127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait list control
Description: 12 week wait list control condition during which participants abstain from aerobic exercise
Study NCT01180127 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list control
Description: 12 week wait list control condition during which participants abstain from aerobic exercise
Study NCT02298621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pomegranate juice
Description: Randomized clinical trial or RCT
Study NCT02298621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pomegranate juice
Description: Randomized clinical trial or RCT
Study NCT02298621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Randomized clinical trial or RCT
Study NCT02298621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Randomized clinical trial or RCT
Study NCT00922961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
Study NCT00922961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical exam
Description: Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
Study NCT03026179 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Play Nicely
Description: Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
Study NCT00646386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg eow Week 0 - Week 24
Study NCT00646386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: 40 mg eow Week 0 - Week 24
Study NCT02175173 — intervention group
Intervention type: DRUG
Intervention: Rufinamide
Description: Administration of Inovelon 100mg or 200mg Tablets
Study NCT01098422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Radioactive Resin Microspheres
Description: An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
Study NCT01968980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 150 mg every 2 weeks, subcutaneous injection, 12 months
Study NCT01968980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection every 2 weeks for 12 months
Study NCT02164409 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy tissue collection
Description: The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
Study NCT00922129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (Rapamune)
Description: Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
Study NCT00922129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin (Neoral) or Tacrolimus (Prograf)
Description: Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months
Study NCT03383666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseRider® Aneurysm Neck Reconstruction Device
Description: Neck Reconstruction Device
Study NCT00549159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Balloon Endometrial Ablation
Description: Thermal balloon endometrial ablation
Study NCT00549159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical Resection of the Endometrium
Description: Transcervical resection of the endometrium
Study NCT01606150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine
Description: 0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
Study NCT01606150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical lidocaine
Description: 1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
Study NCT03124186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S88 Dual Output Stimulator by Grass Technologies
Description: Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
Study NCT03124186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S88 Dual Output Stimulator by Grass Technologies
Description: Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
Study NCT03339596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
Study NCT03339596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
Study NCT03381989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASHI_INTECC Astato XS 20 0.014 guidewire
Description: A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
Study NCT00790673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF 102
Description: Oral capsules
Study NCT00790673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT00101348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00101348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00101348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00101348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01918137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chocolate bar
Study NCT01918137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porridge
Study NCT01023412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Immunonutrition
Description: Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
Study NCT01023412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition
Description: Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
Study NCT01202227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Pregabalin capsules taken twice a daily (150-600mg/day)
Study NCT03456713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC
Study NCT03926767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Description: A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
Study NCT03490994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
Study NCT00940160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX576
Study NCT03490994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin + LMWH
Description: dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
Study NCT01343212 — intervention group
Intervention type: OTHER
Intervention: stiffness measurement using ARFI
Description: Stiffness measurement will be performed for HCC using ARFI technique.
Study NCT03926767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Manual Therapy
Description: A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
Study NCT03926767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orofacial Manual Therapy
Description: A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
Study NCT03926767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Exercises
Description: Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
Study NCT00770393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induction chemotherapy
Description: Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
Study NCT00770393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventionnal chemotherapy
Description: Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion.
Study NCT00133445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-Hep B-IPV Vaccine
Description: U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
Study NCT00133445 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-Hep B-IPV Vaccine
Description: U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.